F-Star gets funding for asset-centric vehicle
A group of venture capitalists is providing €9.4 million to a new company that will hold exclusive licences to oncology assets originated by F-Star Biotechnology Ltd, a discoverer of bispecific antibodies. The Series A round is supported by Atlas Venture.